Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 8—August 2010

CME ACTIVITY

Clostridium difficile Bacteremia, Taiwan1

Nan-Yao Lee, Yu-Tsung Huang, Po-Ren Hsueh2, and Wen-Chien Ko2Comments to Author 
Author affiliations: National Cheng Kung University Hospital and Medical College, Tainan, Taiwan (N.-Y. Lee, W.-C. Ko); National Taiwan University Hospital and College of Medicine, Taipei, Taiwan (Y.-T. Huang, P.-R. Hsueh); 1This study was presented in part at the Annual Meeting of the Infectious Disease Society of Taiwan, Taipei, Taiwan, January 9–10, 2010.; 2These authors contributed equally to this article.

Main Article

Table 3

In vitro antimicrobial drug susceptibilities of 10 bacteremic Clostridium difficile isolates, Taiwan, 1989–2009*

Antimicrobial agent MIC, μg/mL
Resistance breakpoint, μg/mL No. (%) resistant isolates
Range MIC50 MIC90
Vancomycin† 0.5–1 0.5 1 >2 0
Metronidazole 0.25–8 1 4 >32 0
Clindamycin 0.03–>256 4 >256 >8 3 (30)
Penicillin 0.25–8 4 4 >2 9 (90)
Ampicillin/sulbactam 0.5–8 2 4 >32/16 0
Cefmetazole 0.25–32 16 32 >64 0
Meropenem 0.12–2 1 2 >16 0
Imipenem 0.12–16 8 16 >16 4 (40)
Ertapenem 0.06–16 8 8 >16 0
Doripenem 0.12–8 4 4 NA NA
Daptomycin 0.12–2 0.5 2 NA NA
Tigecycline 0.03–0.12 0.03 0.06 NA NA
Fusidic acid 1–8 1 2 NA NA

*MIC50, 50% MIC; MIC90, 90% MIC, NA, not available.
†Vancomycin MIC breakpoint was recommended by the European Committee on Antimicrobial Susceptibility Testing (www.eucast.org); otherwise by the Clinical and Laboratory Standards Institute (22).

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO